Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 31Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 24Busulfan 21Cyclosporine 20Mycophenolic Acid 19Cytarabine 16Antilymphocyte Serum 15Whole-Body Irradiation 14Tacrolimus 14Radiotherapy 13Filgrastim 13Methotrexate 11Melphalan 10Etoposide 10Cord Blood Stem Cell Transplantation 9Methylprednisolone 8sargramostim 6Transplantation 5Idarubicin 5Thiotepa 4Flow Cytometry 4Daunorubicin 4Cytogenetic Analysis 4Immunologic Techniques 3Granulocyte Colony-Stimulating Factor 3Gemtuzumab 3tipifarnib 2merphos 2entinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Abnormalities × temsirolimus × Classical hematology × Clear all
NCT00084916 2013-01-23

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

National Cancer Institute (NCI)

Phase 2 Completed
74 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡